|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.07.25 - 14:36
|
Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business (Business Wire)
|
|
|
SpringWorks immediately adds revenue and accelerates mid- to long-term growth for Merck KGaA, Darmstadt, Germany's Healthcare business sector
Acquisition marks the formation of a rare tumor business for Merck KGaA, Darmstadt, Germany including SpringWorks portfolio and pimicotinib
SpringWorks rare tumor portfolio includes Ogsiveo, a first-in-disease systemic therapy for adults with desmoid tumors and Gomekli a first and only approved therapy for adults and children with NF1-PN
Not intended for UK-based mediaDARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for an enterprise value of $3.4 billion (approximately €3 billion)*, following regulatory clearances and the fulfillment of other customary closing conditions.
The definitive agreement between Merck KGaA, Darmstadt, Germany and SpringWorks, based in Stamford, Connecticut, was announced on 28 April, 2025. I...
|
|
|
01.07.25 - 11:36
|
Merck Buy (DPA-AFX)
|
|
|
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Merck KGaA mit Blick auf das dritte Quartal 2025 auf "Buy" belassen. In den Fokus könnten Nachrichten zum Medikament Varegacestat des US-Biotech-Unternehmens Immunome rücken, ......
|
|
|
|
|
19.06.25 - 08:31
|
Merck KGaA: Hier dürften sich die Bären entscheiden (LYNX)
|
|
|
Die Merck-Aktie ist seit Herbst 2024 ein perfektes „Opfer“ des bärischen Lagers. Obwohl die Analysten durchweg höhere Kursziele sehen, fiel die Aktie wie an der Schnur gezogen. Aber irgendwann ist jeder Bogen überspannt - und der Kurs hat eine wichtige Supportzone erreicht....
|
|
|
18.06.25 - 14:06
|
MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant (Business Wire)
|
|
|
Winner's lead therapy targets Parkinson's disease; platform addresses 6,000+ genetic disorders
Neoclease gains access to MilliporeSigma's technologies and expert support to scale its AI-designed gene-editing platform
The company has awarded 40+ startups globally through Advance Biotech Grant since 2014
BURLINGTON, Mass.--(BUSINESS WIRE)--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced Neoclease as the winner of the 2025 North American Advance Biotech Grant. The Boston-based biotech startup develops AI-designed gene editing therapies for Parkinson's disease.
“We're committed to empowering biotech innovators who are advancing transformative modalities like gene editing,” said Sebastián Arana, Head of Process Solutions, Life Science business of Merck KGaA, Darmstadt, Germany. “By combining Neoclease's AI-designed gene-editing platform with our technologies, regulatory expertise, and process sup...
|
|
|
|
|
|
|
|
|
|
|
03.06.25 - 10:39
|
Merck Overweight (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Merck KGaA mit einem Kursziel von 155 Euro auf "Overweight" belassen. Die auf der Asco-Krebsforschertagung präsentierten Studiendaten zu einem Antikörper gegen Dickdarmkrebs zeigten ......
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
